Sangamo BioSciences Financial Statements
Sangamo BioSciences Financial Information
| Company Type | Public Headquarters |
|---|---|
| Fiscal Year-End | December |
| Annual Report | Company Web Site |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Sangamo BioSciences Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 9.1 | 7.9 | 2.5 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (24.8) | (20.7) | (13.8) |
| Total Net Income ($ mil.) | (21.5) | (17.9) | (13.3) |
| Diluted EPS (Net Income) | (0.58) | (0.55) | (0.51) |
Sangamo BioSciences Quarterly Statements
| Quarter Ending Jun 08 | Quarter Ending Mar 08 | Quarter Ending Dec 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 2.8 | 2.8 | 2.8 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (8.0) | (8.8) | (7.6) |
| Total Net Income ($ mil.) | (7.4) | (8.0) | (6.7) |
| Diluted EPS (Net Income) | (0.18) | (0.20) | (0.17) |
Sangamo BioSciences Stock Quote & Chart
08/21/08 15:00:09 EST •
NASDAQ •
9.93
•
 -0.0500
•
-0.5010 %
|
|---|
|
Quotes delayed 15 minutes for NASDAQ. 20 minutes for NYSE and AMEX. Market Data provided by Interactive Data. Powered and Implemented by Interactive Data Managed Solutions.
|
Sangamo BioSciences Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | 40.91 | 3.75 | 1.56 |
| Price/Earnings Ratio | -- | 16.34 | 15.82 |
| Price/Book Ratio | 7.22 | 2.92 | 1.52 |
| Price/Cash Flow Ratio | -- | 13.17 | 9.88 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Sangamo BioSciences Financial Ratios
Sangamo BioSciences Competitive Intelligence
| Eli Lilly | Merck | Pfizer | |
|---|---|---|---|
| Annual Sales ($ mil.) | 18,633.5 | 24,197.7 | 48,418.0 |
| Employees | 40,600 | 59,800 | 86,600 |
| Market Cap ($ mil.) | 54,960.2 | 77,471.9 | 133,815.6 |
Competitive Landscape
